IPO Databook: Obsidian Therapeutics (OBX US) - Aug 2026

101 Views30 Aug 2026 10:04

SUMMARY

Obsidian Therapeutics is a clinical-stage biopharmaceutical company developing engineered TIL cell therapies for solid tumors using its cytoDRiVE™ platform. Amsoki-cel, its lead candidate, is in Phase 2 for melanoma and.
Amsoki-cel is in Phase 2 for melanoma and Phase 1 for NSCLC. It showed a 67% ORR in melanoma Phase 1/2 and received FDA Fast Track and RMAT designations.
The company incurred significant financial losses since inception and anticipates continued losses, with approximately $186.5 million in federal net operating losses as of December 31, 2025.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream